Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
AveXis logo — Specializing in groundbreaking gene therapies for rare neuro...

AveXis

Specializing in groundbreaking gene therapies for rare neurological genetic diseases, impacting lives profoundly.

Founded 2013 Grant Total: $75.10M Biotechnology, Health Care

General Information

Company Name AveXis
Founded Year 2013
Founders / Decision Makers
Team member
Industries Biotechnology, Health Care
Funding Stage Grant
Social

Get notified when AveXis moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About AveXis

AveXis is a biotechnology startup specializing in groundbreaking gene therapies for rare neurological genetic diseases, impacting lives profoundly. Founded in 2013, the company was later acquired by Novartis on May 14, 2018, and adopted the name Novartis Gene Therapies in 2020. AveXis focuses on developing and bringing to market innovative gene therapies for individuals and families impacted by rare and severe neurological genetic disorders. The company received a $100.00K grant investment on 01 January 2019 from the North Carolina Biotechnology Center. Specializing in the biotechnology and health care industries, AveXis has shown potential for addressing critical medical needs through advanced genetic therapies.

Taxonomy: Gene Therapy, Neurological Genetic Diseases, Rare Diseases, Medical Innovation, Novartis, Acquisition, Life-Threatening Conditions, Research & Development, Therapeutic Innovations

Funding Rounds & Investors (5)

View All
Funding Stage Amount Investors Lead Investors Date
Grant •••••• 1 •••• •••• 01 Jan 2019
Series D •••••• 9
Investor Investor Investor Investor Investor Investor Investor Investor
•••• •••• 		08 Sep 2015
Series C •••••• - 09 Jan 2015
Series B •••••• - 22 Apr 2014
Series A •••••• - 27 Jul 2013

AveXis Alternatives & Competitors

AveXis vs
Kate Therapeutics
Kate Therapeutics United States

New Hope for Patients with Muscle and Heart Disease

Acquired
48 employees
Biotechnology, Health Care
Compare AveXis vs Kate Therapeutics
AveXis vs
Epigenic Therapeutics
Epigenic Therapeutics China

Pioneering Epigenetic Medicine

Series A
13 employees
Biotechnology
AveXis vs
Opus Genetics
Opus Genetics United States

Gene therapy company for inherited retinal diseases

Grant
42 employees
Health Care, Health and Wellness

FAQ About AveXis

Specializing in groundbreaking gene therapies for rare neurological genetic diseases, impacting lives profoundly.
AveXis was founded in 2013.
AveXis operates in the following industries: Biotechnology, Health Care.
AveXis has completed 5 funding rounds, raising a total of $75.10M. The latest funding stage is Grant.
Top alternatives and competitors to AveXis include Kate Therapeutics, Epigenic Therapeutics, Opus Genetics, Abeona Therapeutics, Coave Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
AveXis and Kate Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors AveXis and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy